Why Is Planet Labs Stock Up Today?
Planet Labs (NYSE: PL) opened Friday trading with an unmistakable…
Buy
52
RGLS Quote, Financials, Valuation and Earnings
Last price:
$8.17
Seasonality move
:
-20.08%
Day range:
$8.16 - $8.16
52-week range:
$0.83 - $8.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
8.19x
Volume:
--
Avg. volume:
2M
1-year change:
300%
Market cap:
$565M
Revenue:
--
EPS (TTM):
-$0.73
Analysts' Opinion
-
Consensus RatingRegulus Therapeutics has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $7.00, Regulus Therapeutics has an estimated downside of -1.96% from its current price of $8.16.
-
Price Target UpsideAccording to analysts, the highest upside price target is $7.00 representing -14.22% upside increase from its current price of $8.16.
Fair Value
-
According to the consensus of 2 analysts, Regulus Therapeutics has -1.96% downside to fair value with a price target of $7.00 per share.
RGLS vs. S&P 500
-
Over the past 5 trading days, Regulus Therapeutics has underperformed the S&P 500 by -3.41% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Regulus Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Regulus Therapeutics has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Regulus Therapeutics reported revenues of --.
Earnings Growth
-
Regulus Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Regulus Therapeutics reported earnings per share of -$0.15.
Enterprise value:
499.6M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-11.47x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$29M | -$32.6M | -$51.8M | -$8.8M | -$10.5M | |
| EBITDA | -$27.9M | -$30.6M | -$47.1M | -$8.3M | -$9.5M | |
| Diluted EPS | -$1.82 | -$1.45 | -$0.73 | -$0.29 | -$0.15 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $36.5M | $57.9M | $34.6M | $101.4M | $71.7M | |
| Total Assets | $39.8M | $61M | $37M | $114.1M | $74.8M | |
| Current Liabilities | $9.9M | $4.7M | $8.8M | $5.7M | $4.4M | |
| Total Liabilities | $12.7M | $11.7M | $10.4M | $6.6M | $5.8M | |
| Total Equity | $27.1M | $49.2M | $26.6M | $107.6M | $69M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$27.3M | -$27.4M | -$43.5M | -$8.7M | -$10.6M | |
| Cash From Investing | -$19K | -$79.1M | $64.1M | -$78.5M | $21.5M | |
| Cash From Financing | $3.7M | $105.7M | -$643K | $93.1M | $45K | |
| Free Cash Flow | -$27.5M | -$28.2M | -$43.5M | -$9M | -$10.6M | |
RGLS
Sector
Market Cap
$565M
$33.7M
Price % of 52-Week High
97.78%
47.34%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.79%
1-Year Price Total Return
300%
-35.46%
Beta (5-Year)
0.354
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$8.14
200-day SMA
Buy
Level
$2.83
Bollinger Bands (100)
Buy
Level
0.99 - 7.31
Chaikin Money Flow
Sell
Level
-338.5M
20-day SMA
Buy
Level
$8.11
Relative Strength Index (RSI14)
Buy
Level
66.62
ADX Line
Buy
Level
63.96
Williams %R
Neutral
Level
-31.0924
50-day SMA
Buy
Level
$6.90
MACD (12, 26)
Buy
Level
0.31
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
319.1M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
Stock Forecast FAQ
In the current month, RGLS has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The RGLS average analyst price target in the past 3 months is $7.00.
-
Where Will Regulus Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Regulus Therapeutics share price will drop to $7.00 per share over the next 12 months.
-
What Do Analysts Say About Regulus Therapeutics?
Analysts are divided on their view about Regulus Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Regulus Therapeutics is a Sell and believe this share price will rise from its current level to $7.00.
-
What Is Regulus Therapeutics's Price Target?
The price target for Regulus Therapeutics over the next 1-year time period is forecast to be $7.00 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is RGLS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Regulus Therapeutics is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of RGLS?
You can purchase shares of Regulus Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Regulus Therapeutics shares.
-
What Is The Regulus Therapeutics Share Price Today?
Regulus Therapeutics was last trading at $8.17 per share. This represents the most recent stock quote for Regulus Therapeutics. Yesterday, Regulus Therapeutics closed at $8.16 per share.
-
How To Buy Regulus Therapeutics Stock Online?
In order to purchase Regulus Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Coherent Stock Breaking Out?
Coherent (NYSE: COHR) has spent the better part of two years…
What Is The Long-term Outlook for AMC Stock?
Meme stock extraordinaire AMC Entertainment Holdings, Inc. (NYSE:AMC) has long…
Stock Ideas
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 53x
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 42x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
95
AVAV alert for Jun 27
AeroVironment [AVAV] is up 2.13% over the past day.
Buy
70
AEVA alert for Jun 27
Aeva Technologies [AEVA] is up 8.52% over the past day.
Buy
88
TSSI alert for Jun 27
TSS [TSSI] is down 2.73% over the past day.
